BRIEF published on 08/25/2026 at 19:35, 28 days 20 hours ago New CEO Appointed at KD Pharma Group Pharmaceutical Industry Leadership Change KD Pharma Group Omega-3 Lipids Manja Boerman
BRIEF published on 08/25/2026 at 19:35, 28 days 20 hours ago Nomination d'un nouveau PDG chez KD Pharma Group Changement De Leadership Industrie Pharmaceutique Groupe KD Pharma Manja Boerman Lipides Oméga-3
PRESS RELEASE published on 08/25/2026 at 19:30, 28 days 20 hours ago Change in the Management Board O3 Holding GmbH announces the appointment of Manja Boerman as Chief Executive Officer of KD Pharma Group, bringing extensive industry expertise in pharmaceutical, biotechnology, and life sciences Pharmaceutical Industry Chief Executive Officer O3 Holding GmbH KD Pharma Group Manja Boerman
BRIEF published on 08/21/2026 at 15:20, 1 month 2 days ago O3 Holding GmbH Releases Q2 2026 Interim Report Bond Issue O3 Holding GmbH KD Pharma Group Q2 2026 Report Pharmaceutical Lipids
BRIEF published on 08/21/2026 at 15:20, 1 month 2 days ago O3 Holding GmbH publie son rapport intermédiaire du deuxième trimestre 2026 Emission D'obligations O3 Holding GmbH Groupe KD Pharma Rapport Du Deuxième Trimestre 2026 Lipides Pharmaceutiques
PRESS RELEASE published on 08/21/2026 at 15:15, 1 month 2 days ago O3 Holding GmbH - Publication Q2 2026 Interim Report O3 Holding GmbH, the parent company of KD Pharma Group, releases Q2 2026 Interim Report in compliance with bond terms, available on their website Pharmaceutical O3 Holding GmbH KD Pharma Group Q2 2026 Interim Report Nutritional Lipids
BRIEF published on 05/29/2026 at 18:05, 3 months 24 days ago O3 Holding GmbH Releases Q1 2026 Interim Report Financial Disclosure Bond Issue O3 Holding GmbH KD Pharma Group Q1 2026 Report
BRIEF published on 05/29/2026 at 18:05, 3 months 24 days ago O3 Holding GmbH publie son rapport intermédiaire du premier trimestre 2026 Déclaration Financière Emission D'obligations O3 Holding GmbH Groupe KD Pharma Rapport Du Premier Trimestre 2026
PRESS RELEASE published on 05/29/2026 at 18:00, 3 months 24 days ago O3 Holding GmbH - Publication Q1 2026 Interim Report O3 Holding GmbH announces the publication of its Q1 2026 Interim Report for its FRN Senior Secured EUR 180,000,000 bond issue. Contact investor.relations@kdpharma.com for more info CDMO Interim Report Q1 2026 O3 Holding GmbH KD Pharma Group
BRIEF published on 03/02/2026 at 11:40, 6 months 21 days ago O3 Holding GmbH Releases Q4 2025 Interim Report Financial Results Bond Issue O3 Holding GmbH KD Pharma Group Q4 2025 Interim Report
Published on 09/23/2026 at 14:31, 1 hour 11 minutes ago First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 1 hour 12 minutes ago Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 14:00, 1 hour 42 minutes ago Integrated Rewards Launches "Celebrate Canadian" Campaign to Connect Canadian Brands with Millions of Consumers
Published on 09/23/2026 at 13:30, 2 hours 12 minutes ago Engineering Cost Study Validates Commercial-Scale U.S. HPMSM Capital Cost and Establishes EMM Capital Cost for Electric Metals' North Star Manganese Project
Published on 09/23/2026 at 13:30, 2 hours 12 minutes ago Green Bridge Metals Corporation Announces Phase 2 Diamond Drill Program at the Titac Titanium-Copper-Vanadium Project, Minnesota, USA
Published on 09/23/2026 at 15:37, 5 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 09/23/2026 at 08:00, 7 hours 42 minutes ago Résultats semestriels 2026 - ANR par action : 101,90 €, en progression de 8,18 % - Capitaux propres consolidés : 774,5 M€
Published on 09/22/2026 at 18:00, 21 hours 42 minutes ago Consolidated results for the first half of 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 18:00, 21 hours 42 minutes ago Résultats consolidés du premier semestre 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 17:45, 21 hours 57 minutes ago Imerys-09-2026-information-share-capital-and-voting-rights-as-of-31-August-2026
